13:09 , Jun 8, 2018 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...
22:45 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest CAR T cells targeting GD2 could help treat diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas harboring the H3.3A K27M mutation. In co-culture with patient-derived...